Meeting Banner
Abstract #2284

Metabolomics study of urine discriminates prostate cancer (PCa) patients from benign prostatic hyperplasia (BPH) by 1H NMR spectroscopy

Pradeep Kumar1, Rajeev Kumar2, Virendra Kumar1, S. Senthil Kumaran1, Sanjay Sharma3, Sanjay Thulkar3, S. Datta Gupta4, and Naranamangalam R. Jagannathan1

1Department of NMR & MRI Facility, India Institute of Medical Sciences, New Delhi, India, NEW DELHI, India, 2Department of Urology, India Institute of Medical Sciences, New Delhi, India, New Delhi, India, 3Department of Radio-diagnosis, All India Institute of Medical Sciences, New Delhi, India, New Delhi, India, 4Department of Pathology, All India Institute of Medical Sciences, New Delhi, India, New Delhi, India

The present study demonstrates the potential of proton nuclear magnetic resonance (1H-NMR) based metabolic profiling of urine for distinguishing prostate cancer patients (PCa; n=43) from patients with benign prostatic hyperplasia (BPH; n=30) and to determine non-invasive biomarker/s for diagnosis. A significantly lower concentration of leucine, valine, hippurate, dimethylglycine, glycerophosphocholine, glutamine, glycine, taurine and creatinine were observed in PCa patients as compared to BPH. Our result suggests metabolic alterations due to protein turnover, cell proliferation, energy demand and gut micro-biota metabolism in PCa patients.

This abstract and the presentation materials are available to members only; a login is required.

Join Here